Beatrix Stelte-Ludwig

This inventor holds 27 USPTO granted patents and 30 published patent applications, plus 3 CIPO patents and 8 EPO patents, primarily in Antibody Drug Conjugates. Top assignees: Bayer Pharma Aktiengesellschaft, Bayer Aktiengesellschaft, Seattle Genetics, Inc.. Active years: 2001-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Beatrix Stelte-Ludwig. Retrieved from https://idiyas.com/inventor/beatrix-stelte-ludwig

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 27 (Patent Applications = 30)

% Patents Active = 74.1

CIPO Patents = 3 (Patent Applications = 23)

EPO Patents = 8 (Patent Applications = 41)

Average Co-Inventor Count = 9.0

ph-index = 8

Forward Citations = 162(Granted Patents)

Location History:

Wuelfrath, DE (2001 - 2003)
Wulfrath, DE (2002 - 2014)
Wülfrath, DE (2002 - 2024)

Company Filing History:

15 out of 387

Bayer Pharma Aktiengesellschaft

patents

10 out of 12,269

Bayer Aktiengesellschaft

patents

4 out of 132

Seattle Genetics, Inc.

where one patent can have more than one assignee

Years Active: 2001-2024

Loading Chart...

Areas of Expertise:

Antibody Drug Conjugates

KSP Inhibitors

Cytotoxic Agents

Enzymatically Cleavable Groups

Prodrugs

Specific Antibodies

Integrin Antagonists

Auristatin Derivatives

Binder-Drug Conjugates

Multiheterocyclic Pharmaceuticals

Biphenyl Compounds

Site Specific Homogeneous

27 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12144865 - Antibody drug conjugates with enzymatically cleavable groups (2024-11-19),

2. 12065497 - Methods of treatment using CCR8 antibodies (2024-08-20),

3. 12059472 - Prodrugs of cytotoxic active agents having enzymatically cleavable groups (2024-08-13),

4. 11806404 - Site specific homogeneous with KSP inhibitors (2023-11-07),

5. 11685714 - Prodrugs of cytotoxic active agents having enzymatically cleavable groups (2023-06-27),

6. 11660351 - Antibody drug conjugates (ADCs) having enzymatically cleavable groups (2023-05-30),

7. 11643469 - Specific antibody-drug-conjugates (ADCs) with KSP inhibitors and anti-CD123-antibodies (2023-05-09),

8. 11478554 - Antibody drug conjugates (ADCS) having enzymatically cleavable groups (2022-10-25),

9. 11433140 - Specific antibody drug conjugates (ADCs) having KSP inhibitors (2022-09-06),

10. 11123439 - Antibody drug conjugates (ADCS) and antibody prodrug conjugates (APDCS) with enzymatically cleavable groups (2021-09-21),

11. 11071788 - Antibody drug conjugates of kinesin spindel protein (KSP) inhibitors with antiB7H3-antibodies (2021-07-27),

12. 11001636 - Specific antibody-drug-conjugates (ADCs) with KSP inhibitors and anti-CD123-antibodies (2021-05-11),

13. 10973923 - Site specific homogeneous with KSP inhibitors (2021-04-13),

14. 10744205 - Antibody drug conjugates of kinesin spindel protein (KSP) inhibitors with anti-CD123-antibodies (2020-08-18),

15. 10485880 - Antibody-drug conjugates (ADCs) of KSP inhibitors with aglycosylated anti-TWEAKR antibodies (2019-11-26),

As an AI assistant specialized in innovations, inventions, inventors, patent attorneys, assignees, and patents, I can provide you with well-structured articles on various figures in these fields. If you have any requests regarding these specific topics, feel free to ask!

Profile summary based on public USPTO records.